Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Gottlieb

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
NAM Perspectives|June 10, 2024
Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and TechnologyDebra Mathews, Amy Abernethy, Elliot Chaikof, et al.
Pharmacogenomics|December 15, 2010
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programsLinda C Surh, Michael A Pacanowski, Susanne B Haga, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for StakeholdersPhilip E Johnson, George Dahlman, Kirby Eng, et al.
The Pan African Medical Journal|November 7, 2019
[HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)]Selly Ba, Ndeye Mery Dia-Badiane, Stephen Edward Hawes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectivesAndrew D Zelenetz, Islah Ahmed, Edward Louis Braud, et al.
JAMA Dermatology|September 21, 2022
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical TrialJoel M Gelfand, Daniel B Shin, April W Armstrong, et al.
The Journal of Investigative Dermatology|February 24, 2020
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
NAM Perspectives|June 10, 2024
Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and TechnologyDebra Mathews, Amy Abernethy, Elliot Chaikof, et al.
Pharmacogenomics|December 15, 2010
Learning from product labels and label changes: how to build pharmacogenomics into drug-development programsLinda C Surh, Michael A Pacanowski, Susanne B Haga, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2010
NCCN Oncology Risk Evaluation and Mitigation Strategies White Paper: Recommendations for StakeholdersPhilip E Johnson, George Dahlman, Kirby Eng, et al.
The Pan African Medical Journal|November 7, 2019
[HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)]Selly Ba, Ndeye Mery Dia-Badiane, Stephen Edward Hawes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectivesAndrew D Zelenetz, Islah Ahmed, Edward Louis Braud, et al.
JAMA Dermatology|September 21, 2022
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical TrialJoel M Gelfand, Daniel B Shin, April W Armstrong, et al.
The Journal of Investigative Dermatology|February 24, 2020
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, et al.
Pageof 9